ClinicalTrials.gg
TerminatedNCT04940949Updated Mar 16, 2023

A Study to Evaluate Lu AF90103 in Healthy Men

A Phase 1 interventional study of Lu AF90103 and Placebo in Healthy, sponsored by H. Lundbeck A/S. Terminated at 1 site in Netherlands. Open to male participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-03-16.

Sponsored by H. Lundbeck A/S · Phase 1, Interventional, and Treatment

How we know

Why this study was terminated
The study was terminated based on new safety data.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
15
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
Male
01

Study summary

The purpose of this study is to investigate the safety and tolerability of Lu AF90103 and what the body does to Lu AF90103 after single doses of the drug administered directly into a vein.

Read the detailed description

This study is the first-in-human (FIH) study with Lu AF90103. The study is divided in two parts, Part A and Part B.

Part A is an interventional, randomized, double-blind, sequential-group, placebo-controlled, single-ascending dose study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of Lu AF90103 in healthy men.

Part B is an interventional, randomized, double-blind, cross-over study to investigate the safety profile after administration of Lu AF90103 as an infusion at two different rates to healthy young men.

The dosage in Part B is guided by the cohorts in Part A and is a repetition of one of the doses from Part A.

The total study duration per participant from baseline to the end of follow-up will be maximum 11 days in Part A and 16 days in Part B.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

H. Lundbeck A/S is the lead sponsor of 224 studies on the registry; 9 are open to participants now.

Of its 33 completed or terminated interventional studies of FDA-regulated products, 10 (30%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The participant is ≥18 and ≤45 years of age at the Screening Visit for Cohorts A1 to A6 (excluding cohort A2b) or ≥55 to ≤65 for participants in the CSF sampling Cohorts A2b and A7.
  • The participant has (BMI) ≥18.5 kilograms (kg)/square meter (m\^2) and ≤30 kg/m\^2 and body weight ≥60 kilograms (kg) at the Screening Visit and at the Baseline Visit.
  • The participant has a normal resting electroencephalogram (EEG) at Screening.
  • The participant is, in the opinion of the investigator, generally healthy based on medical history, a physical examination, vital signs, an (ECG), and the results of the clinical chemistry, haematology, urinalysis, serology, and other laboratory tests.

Exclusion criteria

Exclusion Criteria:

  • The participant has or has had any immunological, cardiovascular, respiratory, metabolic, renal, hepatic, gastrointestinal, endocrinological, haematological, dermatological, venereal, neurological, or psychiatric disease or other major disorder.

Other inclusion and exclusion criteria may apply.

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Investigator)
Enrollment
15 participants (actual)

Study arms

  • Experimental
    Single Intravenous (IV) Dose of Lu AF90103

    Participants will receive a single IV dose of Lu AF90103.

    Drug: Lu AF90103

  • Placebo comparator
    Single IV Dose of Placebo

    Participants will receive a single IV dose of placebo matching to Lu AF90103.

    Drug: Placebo

  • Experimental
    2 Single IV Doses of Lu AF90103

    Participants will receive 2 single IV doses of Lu AF90103 separated by at least 5 days.

    Drug: Lu AF90103

Interventions

  • DrugLu AF90103

    Lu AF90103 - powder for solution for infusion

  • DrugPlacebo

    Placebo - powder for solution for infusion

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment-Emergent Adverse Events

    Time frame: From dosing (Day 1) to Day 16

  2. Maximum Observed Concentration (Cmax) of Lu AF90103 and AF88361 in Plasma and Cerebrospinal Fluid (CSF)

    Time frame: 0 (predose) up to 96 hours postdose on Day 1 to Day 5

  3. Area Under the Plasma Concentration-Time Curve From Time Zero to Infinity (AUC0-inf) of Lu AF90103 and AF88361 in Plasma and CSF

    Time frame: 0 (predose) up to 96 hours postdose on Day 1 to Day 5

  4. Total Clearance (CL) of Lu AF90103 and AF88361

    Time frame: 0 (predose) up to 96 hours postdose on Day 1 to Day 5

  5. Amount of Lu AF90103 and Lu AF88361 Excreted in Urine

    Time frame: 0 (predose) up to 96 hours postdose on Day 1 to Day 5

  6. Changes to Time Matched Baseline in Area Under the Curve (AUC) of Medial Prefrontal (FZ and CZ Electrodes) High Frequency Gamma Signal (100-170 Hertz [HZ]) for Lu AF90103 at the Resting State

    The AUC of medial prefrontal (FZ and CZ electrodes) high frequency gamma signal (100-170 HZ) will be derived for Lu AF90103 at resting state, as measured by electroencephalogram (EEG).

    Time frame: From dosing (Day 1) to Day 4 (Part A) and Day 9 (Part B)

07

Study locations

1 site
  • QPS Netherlands B.V.
    GZ Groningen, 9713, Netherlands
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2021 to primary completion in Nov 2021, 5 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 27, 2021
First posted
Jun 28, 2021
StartActual
May 26, 2021
Primary completionActual
Nov 23, 2021
CompletionActual
Nov 23, 2021
Last update
Mar 16, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 16, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04940949
Lead sponsor
H. Lundbeck A/S
Responsible party
Sponsor
First posted
Jun 28, 2021
Start date
May 26, 2021
Primary completion
Nov 23, 2021
Completion
Nov 23, 2021
Last update
Mar 16, 2023

Study contacts

Email contact via H. Lundbeck A/S
study director · LundbeckClinicalTrials@Lundbeck.com

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion